多索茶碱联合异丙托溴铵治疗支气管哮喘急性发作疗效探讨

Therapeutic Effect of Doxofylline Combined with Ipratropium Bromide on Acute Exacerbation of Bronchial Asthma

目的探讨多索茶碱联合异丙托溴铵治疗支气管哮喘急性发作的临床疗效。方法选取2017年1月-2019年1月间该院呼吸科收治的120例支气管哮喘急性发作患者作为研究对象,随机分为研究组与对照组,每组60例。对照组采取异丙托溴铵治疗,研究组在此基础上联合多索茶碱治疗,比较两组患者治疗效果。结果治疗前,两组患者FEV1水平比较差异无统计学意义(t=0.283,P=0.777>0.05);治疗后,研究组FEV1水平要高于对照组(t=2.934,P=0.004<0.05);治疗前,两组患者PEF水平比较差异无统计学意义(t=0.313,P=0.755>0.05);治疗后,研究组PEF水平要高于对照组(t=5.508,P=0.001<0.05);治疗前,两组患者FEV1/FVC水平比较差异无统计学意义(t=0.388,P=0.698>0.05);治疗后,研究组FEV1/FVC水平要高于对照组(t=8.565,P=0.001<0.05)。研究组不良反应发生率为18.33%,对照组为16.67%,两组比较差异无统计学意义(χ^2=0.058,P=0.810)。研究组总有效率(98.33%)较对照组(86.67%)更高(χ^2=5.886,P=0.015<0.05)。结论多索茶碱联合异丙托溴铵治疗支气管哮喘急性发作效果较优,不良反应较少,可改善患者肺功能指标,稳定患者病情。

Objective To investigate the clinical efficacy of doxofylline combined with ipratropium bromide in the treatment of acute asthma attack. Methods 120 patients with acute exacerbation of bronchial asthma admitted to thehospital from January 2017 to January 2019 were selected as subjects,they were randomly divided into study group and control group, with 60 cases in each group. The control group was treated with ipratropium bromide. The study group was treated with doxofylline on the basis of this, the therapeutic effects of the two groups of patients were compared.Results Before treatment, there was no significant difference in FEV1 levels between the two groups(t =0.283, P =0.777>0.05). After treatment, the FEV1 level of the study group was higher than that of the control group(t=2.934, P=0.004<0.05). Before treatment, there was no significant difference in PEF levels between the two groups(t=0.313, P=0.755 >0.05). After treatment, the PEF level of the study group was higher than that of the control group(t=5.508, P=0.001<0.05). Before treatment, there was no significant difference in FEV1/FVC levels between the two groups(t=0.388,P=0.698 >0.05). After treatment, the FEV1/FVC levels in the study group were higher than that in the control group(t=8.565, P=0.001<0.05). The incidence of adverse reactions was 18.33% in the study group and 16.67% in the control group. There was no statistically significant difference between the two groups(χ^2=0.058, P=0.810 >0.05). The total effective rate of the study group(98.33%) was higher than that of the control group(86.67%)(χ^2=5.886, P=0.015 <0.05).Conclusion Doxofylline combined with ipratropium bromide is effective in the treatment of acute asthma attack, and has fewer adverse reactions, which can improve the lung function index and stabilize the patient’s condition.